Pneumocystis Pneumonia

Risk Factors

HIV/AIDS with CD4 count < 200 cells/μL, CD4 percentage < 14%, chronic corticosteroid use (equivalent to prednisone ≥ 20 mg/day for ≥ 3 weeks), solid organ transplant recipients, hematologic malignancies, patients on chemotherapy or other immunosuppressive agents

Etiology

Pneumocystis jirovecii (formerly P. carinii), an atypical fungus that lacks ergosterol in its cell membrane

Presentation

Gradual onset over days to weeks of progressive exertional dyspnea, nonproductive (dry) cough, and low-grade fever. The subacute timeline is a hallmark.

Classic Exam

Exam findings are often disproportionately mild compared to the degree of hypoxia. Lung auscultation may be clear or show only faint bilateral crackles. Tachypnea and tachycardia are common. Oral thrush may coexist as a clue to immunosuppression.

Diagnostics

Chest X-ray: bilateral diffuse ground-glass or interstitial infiltrates (perihilar predominance). Elevated serum LDH. Elevated serum beta-D-glucan. Arterial blood gas showing hypoxemia with widened $A\text{-}a\ \text{gradient}$ . Definitive diagnosis by induced sputum or bronchoalveolar lavage (BAL) with Grocott methenamine silver (GMS) stain or direct fluorescent antibody (DFA).

Management

Trimethoprim-sulfamethoxazole (TMP-SMX) is first-line for both treatment and prophylaxis. Add adjunctive corticosteroids if $PaO_2 < 60\ \text{mmHg}$ or $A\text{-}a\ \text{gradient} \geq 35\ \text{mmHg}$ on room air.

Keywords

"Bilateral ground-glass opacities," "CD4 < 200," "subacute dyspnea," "nonproductive cough," "elevated LDH," "hypoxia out of proportion to exam," "immunocompromised host"

01Pathophysiology

Pneumocystis jirovecii is classified as an atypical fungus. Unlike most pathogenic fungi, it lacks ergosterol in its cell membrane. This is a critical teaching point because it explains why traditional antifungal agents such as amphotericin B and azole antifungals are completely ineffective against this organism. The absence of ergosterol renders drugs targeting the ergosterol synthesis pathway useless.

The organism is acquired through airborne transmission and colonizes the alveolar spaces. In immunocompetent individuals, CD4+ T-helper cells effectively clear the organism before it causes disease. In the immunocompromised host, particularly when the CD4 count drops below 200 cells/μL, the weakened cellular immune response allows P. jirovecii to proliferate unchecked within the alveoli.

As the organisms multiply, they provoke an inflammatory response that leads to the accumulation of a foamy, eosinophilic, proteinaceous exudate within the alveolar spaces. This exudate coats the alveolar walls and fills the airspaces, creating a physical barrier to gas exchange. The result is impaired oxygen diffusion across the alveolar-capillary membrane. This mechanism explains the hallmark clinical finding: significant hypoxemia (often with a $P a O_{2}$ well below 70 mmHg) that appears disproportionately severe relative to what is heard on lung auscultation.

The elevated serum LDH seen in PCP reflects ongoing lung parenchymal damage and cellular turnover. While LDH elevation is nonspecific, in the right clinical context (immunosuppressed patient with subacute respiratory symptoms), a very high LDH strongly supports PCP. The bilateral ground-glass pattern on chest imaging corresponds directly to the diffuse alveolar filling by the proteinaceous exudate.

The organism's cell wall contains beta-D-glucan, a polysaccharide component shared among many fungi. Because P. jirovecii is technically a fungus, serum beta-D-glucan levels are elevated, providing an important screening biomarker. However, because beta-D-glucan is present in many fungal species, it is sensitive but not organism-specific.

02Classification and Clinical Manifestation

PCP is stratified into two severity categories based on oxygenation parameters, and this classification directly determines whether adjunctive corticosteroids are indicated.

Mild to Moderate

Oxygenation Criteria: $PaO_2 > 70\ \text{mmHg}$ and $A\text{-}a\ \text{gradient} < 35\ \text{mmHg}$ on room air
Clinical Features: Exertional dyspnea, dry cough, low-grade fever; able to tolerate oral medications; O2 saturation relatively preserved at rest
Steroid Indication: No adjunctive steroids needed

Moderate to Severe

Oxygenation Criteria: $PaO_2 \leq 70\ \text{mmHg}$ or $A\text{-}a\ \text{gradient} \geq 35\ \text{mmHg}$ on room air
Clinical Features: Dyspnea at rest, marked tachypnea, inability to maintain saturation, may progress to respiratory failure
Steroid Indication: Adjunctive corticosteroids required (must be started before or with antimicrobial therapy)

Severity	Oxygenation Criteria	Clinical Features	Steroid Indication
Mild to Moderate	$PaO_2 > 70\ \text{mmHg}$ and $A\text{-}a\ \text{gradient} < 35\ \text{mmHg}$ on room air	Exertional dyspnea, dry cough, low-grade fever; able to tolerate oral medications; O2 saturation relatively preserved at rest	No adjunctive steroids needed
Moderate to Severe	$PaO_2 \leq 70\ \text{mmHg}$ or $A\text{-}a\ \text{gradient} \geq 35\ \text{mmHg}$ on room air	Dyspnea at rest, marked tachypnea, inability to maintain saturation, may progress to respiratory failure	Adjunctive corticosteroids required (must be started before or with antimicrobial therapy)

Clinical Manifestation by System

System	Findings
Pulmonary	Progressive exertional dyspnea evolving over 1 to 4 weeks, nonproductive cough, tachypnea. Lung exam may be surprisingly clear.
Constitutional	Low-grade fever, malaise, weight loss, night sweats
Oropharyngeal	Concurrent oral thrush (oropharyngeal candidiasis) is frequently present and serves as a clinical clue to underlying immunosuppression
Extrapulmonary (rare)	Hepatosplenomegaly, lymphadenopathy, bone marrow involvement, choroidal lesions; more common in patients receiving aerosolized pentamidine prophylaxis (which protects only the lungs)

03Diagnostic Workup

Chest X-ray

Role: Best initial imaging study
Key Findings: Bilateral diffuse ground-glass or reticular interstitial infiltrates with perihilar predominance; may be normal early in disease

High-resolution CT chest

Role: More sensitive than CXR if CXR is normal
Key Findings: Bilateral ground-glass opacities, often patchy; may show cystic changes (pneumatoceles)

Arterial blood gas (ABG)

Role: Severity assessment and steroid decision
Key Findings: Hypoxemia, widened $A\text{-}a\ \text{gradient}$ ; determines need for adjunctive steroids

Serum LDH

Role: Supportive/screening
Key Findings: Elevated (often > 500 IU/L); sensitive but nonspecific; a normal LDH argues against PCP

Serum beta-D-glucan

Role: Screening biomarker
Key Findings: Elevated; high sensitivity (~95%), moderate specificity; elevated in many fungal infections

Induced sputum with GMS or DFA stain

Role: Best initial diagnostic test for organism identification
Key Findings: Visualization of P. jirovecii cysts or trophozoites; sensitivity 50 to 80%

Bronchoalveolar lavage (BAL) with GMS or DFA stain

Role: Gold standard / most accurate test
Key Findings: Sensitivity > 95%; performed when induced sputum is negative but clinical suspicion remains high

PCR (on sputum or BAL fluid)

Role: Adjunctive molecular test
Key Findings: Very high sensitivity; may be positive in colonization without active disease, so interpretation requires clinical correlation

Test	Role	Key Findings
Chest X-ray	Best initial imaging study	Bilateral diffuse ground-glass or reticular interstitial infiltrates with perihilar predominance; may be normal early in disease
High-resolution CT chest	More sensitive than CXR if CXR is normal	Bilateral ground-glass opacities, often patchy; may show cystic changes (pneumatoceles)
Arterial blood gas (ABG)	Severity assessment and steroid decision	Hypoxemia, widened $A\text{-}a\ \text{gradient}$ ; determines need for adjunctive steroids
Serum LDH	Supportive/screening	Elevated (often > 500 IU/L); sensitive but nonspecific; a normal LDH argues against PCP
Serum beta-D-glucan	Screening biomarker	Elevated; high sensitivity (~95%), moderate specificity; elevated in many fungal infections
Induced sputum with GMS or DFA stain	Best initial diagnostic test for organism identification	Visualization of P. jirovecii cysts or trophozoites; sensitivity 50 to 80%
Bronchoalveolar lavage (BAL) with GMS or DFA stain	Gold standard / most accurate test	Sensitivity > 95%; performed when induced sputum is negative but clinical suspicion remains high
PCR (on sputum or BAL fluid)	Adjunctive molecular test	Very high sensitivity; may be positive in colonization without active disease, so interpretation requires clinical correlation

The workup begins with a chest X-ray, which is the best initial imaging study. The classic pattern is bilateral, symmetric, diffuse ground-glass or interstitial infiltrates that predominate in the perihilar regions and spread peripherally. However, early in the disease course, the chest X-ray may appear normal. If the clinical suspicion is high but the X-ray is unremarkable, a high-resolution CT (HRCT) of the chest is the next step; it is considerably more sensitive and will typically reveal ground-glass opacities.

An arterial blood gas is essential not only for confirming hypoxemia but for guiding the steroid decision. The two thresholds to remember are $PaO_2 \leq 70\ \text{mmHg}$ and $A\text{-}a\ \text{gradient} \geq 35\ \text{mmHg}$ on room air. Meeting either criterion classifies the disease as moderate-to-severe and mandates adjunctive corticosteroids.

Serum LDH and serum beta-D-glucan are both useful screening markers. LDH is almost always elevated in PCP, and a normal LDH has strong negative predictive value. Beta-D-glucan has high sensitivity (approximately 95%) but is not organism-specific, meaning it can be elevated in candidiasis, aspergillosis, and other invasive fungal infections.

For definitive organism identification, the best initial diagnostic test is an induced sputum sample stained with Grocott methenamine silver (GMS) stain or examined with direct fluorescent antibody (DFA). GMS stains the cyst walls of P. jirovecii and appears as crushed ping-pong ball or crescent-shaped structures. The sensitivity of induced sputum ranges from 50 to 80%.

If induced sputum is negative or nondiagnostic, the most accurate test (gold standard) is bronchoalveolar lavage (BAL) with the same staining techniques. BAL sensitivity exceeds 95% and is definitive.

A key principle: never withhold empiric treatment while awaiting confirmatory testing. In a critically ill immunosuppressed patient with a compatible presentation, start TMP-SMX immediately. The organisms persist in the lungs for days to weeks after treatment initiation, so diagnostic yield from BAL is preserved even after several days of therapy.

04Management and Treatment

First-line treatment

Regimen: TMP-SMX
Details: 15 to 20 mg/kg/day of the TMP component, divided into 3 to 4 doses (q6h or q8h), for 21 days (in HIV) or 14 days (in non-HIV immunosuppressed)

Adjunctive corticosteroids

Regimen: Prednisone (for moderate-to-severe disease)
Details: Days 1 to 5: 40 mg PO twice daily; Days 6 to 10: 40 mg PO once daily; Days 11 to 21: 20 mg PO once daily. Must be started within 72 hours of antimicrobial initiation, ideally before or concurrently.

Alternative (mild-moderate, TMP-SMX intolerant)

Regimen: Atovaquone 750 mg PO twice daily with food
Details: Less effective than TMP-SMX; reserved for mild disease and sulfa allergy

Alternative (mild-moderate)

Regimen: Dapsone + Trimethoprim
Details: Dapsone 100 mg PO daily + Trimethoprim 5 mg/kg PO q8h

Alternative (moderate-severe, TMP-SMX intolerant)

Regimen: IV Pentamidine 4 mg/kg IV once daily
Details: Second-line for severe disease; associated with nephrotoxicity, hypotension, hypoglycemia, and pancreatitis

Alternative (moderate-severe)

Regimen: Clindamycin + Primaquine
Details: Clindamycin 600 to 900 mg IV q6-8h + Primaquine 30 mg PO daily

Primary prophylaxis

Regimen: TMP-SMX 1 DS tablet PO daily
Details: Initiate when CD4 < 200 cells/μL, CD4% < 14%, or history of oropharyngeal candidiasis. Alternative: Dapsone 100 mg daily, or Atovaquone 1500 mg daily, or Aerosolized Pentamidine 300 mg monthly via nebulizer

Discontinue prophylaxis

Regimen: When CD4 > 200 cells/μL for ≥ 3 months on ART
Details: Immune reconstitution allows safe discontinuation

Component	Regimen	Details
First-line treatment	TMP-SMX	15 to 20 mg/kg/day of the TMP component, divided into 3 to 4 doses (q6h or q8h), for 21 days (in HIV) or 14 days (in non-HIV immunosuppressed)
Adjunctive corticosteroids	Prednisone (for moderate-to-severe disease)	Days 1 to 5: 40 mg PO twice daily; Days 6 to 10: 40 mg PO once daily; Days 11 to 21: 20 mg PO once daily. Must be started within 72 hours of antimicrobial initiation, ideally before or concurrently.
Alternative (mild-moderate, TMP-SMX intolerant)	Atovaquone 750 mg PO twice daily with food	Less effective than TMP-SMX; reserved for mild disease and sulfa allergy
Alternative (mild-moderate)	Dapsone + Trimethoprim	Dapsone 100 mg PO daily + Trimethoprim 5 mg/kg PO q8h
Alternative (moderate-severe, TMP-SMX intolerant)	IV Pentamidine 4 mg/kg IV once daily	Second-line for severe disease; associated with nephrotoxicity, hypotension, hypoglycemia, and pancreatitis
Alternative (moderate-severe)	Clindamycin + Primaquine	Clindamycin 600 to 900 mg IV q6-8h + Primaquine 30 mg PO daily
Primary prophylaxis	TMP-SMX 1 DS tablet PO daily	Initiate when CD4 < 200 cells/μL, CD4% < 14%, or history of oropharyngeal candidiasis. Alternative: Dapsone 100 mg daily, or Atovaquone 1500 mg daily, or Aerosolized Pentamidine 300 mg monthly via nebulizer
Discontinue prophylaxis	When CD4 > 200 cells/μL for ≥ 3 months on ART	Immune reconstitution allows safe discontinuation

TMP-SMX is the undisputed first-line agent for both treatment and prophylaxis. It works by inhibiting folate synthesis in P. jirovecii through a sequential enzyme blockade (trimethoprim inhibits dihydrofolate reductase; sulfamethoxazole inhibits dihydropteroate synthase). The treatment dose is 15 to 20 mg/kg/day based on the trimethoprim component, divided every 6 to 8 hours, for a total duration of 21 days in HIV-positive patients. Non-HIV immunosuppressed patients are typically treated for 14 days.

The most testable management decision in PCP is the indication for adjunctive corticosteroids. Steroids reduce the inflammatory response in the alveoli and decrease the risk of respiratory deterioration during the first few days of treatment (when dying organisms release inflammatory debris). The indication is moderate-to-severe disease, defined by $PaO_2 \leq 70\ \text{mmHg}$ or $A\text{-}a\ \text{gradient} \geq 35\ \text{mmHg}$ on room air. The steroid taper follows a strict 21-day schedule: 40 mg twice daily for 5 days, then 40 mg once daily for 5 days, then 20 mg once daily for 11 days. Critically, steroids must be initiated before or concurrently with antimicrobial therapy, not after. Starting steroids more than 72 hours into treatment provides no demonstrated benefit.

For patients with sulfa allergy, the choice of alternative depends on disease severity. For mild-to-moderate disease, atovaquone or dapsone plus trimethoprim are options. For moderate-to-severe disease, IV pentamidine or clindamycin plus primaquine are used. Before starting dapsone, check a G6PD level, as dapsone can trigger hemolytic anemia in G6PD-deficient patients.

Primary prophylaxis with TMP-SMX (one double-strength tablet daily) is initiated when CD4 falls below 200 cells/μL, when CD4 percentage is below 14%, or when the patient has a history of oropharyngeal candidiasis. TMP-SMX prophylaxis has the added benefit of providing cross-protection against Toxoplasma gondii encephalitis. Prophylaxis can be safely discontinued once the CD4 count has been above 200 cells/μL for at least 3 consecutive months on effective antiretroviral therapy.

05Differential Diagnosis and Distractors

Bacterial community-acquired pneumonia

Why It Looks Similar: Cough, fever, dyspnea, and pulmonary infiltrates in an immunocompromised patient
Key Discriminator: Bacterial pneumonia presents acutely (hours to 1 to 2 days) with productive purulent cough, focal lobar consolidation, and often pleuritic chest pain. PCP is subacute (weeks) with a dry cough and diffuse bilateral infiltrates.

Pulmonary tuberculosis

Why It Looks Similar: HIV patient with cough, fever, weight loss, and bilateral infiltrates (especially when CD4 < 200 and TB presents atypically)
Key Discriminator: TB often shows upper lobe predominance, cavitation (when CD4 is higher), or hilar/mediastinal lymphadenopathy. TB produces a productive cough, sometimes with hemoptysis. Sputum AFB smear/culture and positive nucleic acid amplification test distinguish TB.

CMV pneumonitis

Why It Looks Similar: Immunosuppressed host (especially transplant recipients) with bilateral interstitial infiltrates and hypoxia
Key Discriminator: CMV pneumonitis is more common in transplant recipients than in HIV. Look for concurrent CMV retinitis or viremia. BAL with cytology showing owl-eye intranuclear inclusions confirms CMV.

Pulmonary Kaposi sarcoma

Why It Looks Similar: HIV/AIDS patient with dyspnea and bilateral pulmonary infiltrates
Key Discriminator: Kaposi sarcoma produces nodular lesions (not ground-glass) on imaging, often with associated pleural effusions and skin/mucosal violaceous lesions. Bronchoscopy reveals characteristic violaceous endobronchial plaques.

Mycobacterium avium complex (MAC)

Why It Looks Similar: AIDS patient with constitutional symptoms, fever, and weight loss
Key Discriminator: MAC typically occurs at CD4 < 50 (lower threshold than PCP). MAC is primarily a disseminated systemic disease (fever, hepatosplenomegaly, elevated alkaline phosphatase, cytopenias) rather than isolated pulmonary disease. Blood cultures are diagnostic.

Lymphocytic interstitial pneumonitis (LIP)

Why It Looks Similar: HIV-associated bilateral interstitial infiltrates with dyspnea
Key Discriminator: LIP predominantly affects children with HIV, not adults. It presents with reticulonodular infiltrates, parotid enlargement, and digital clubbing, developing over months.

Drug-induced pneumonitis (e.g., methotrexate lung)

Why It Looks Similar: Immunosuppressed patient on methotrexate with bilateral ground-glass opacities and dyspnea
Key Discriminator: History of methotrexate or bleomycin use, absence of elevated beta-D-glucan, and negative GMS/DFA staining on BAL. Temporal relationship to drug initiation is the key.

Differential	Why It Looks Similar	Key Discriminator
Bacterial community-acquired pneumonia	Cough, fever, dyspnea, and pulmonary infiltrates in an immunocompromised patient	Bacterial pneumonia presents acutely (hours to 1 to 2 days) with productive purulent cough, focal lobar consolidation, and often pleuritic chest pain. PCP is subacute (weeks) with a dry cough and diffuse bilateral infiltrates.
Pulmonary tuberculosis	HIV patient with cough, fever, weight loss, and bilateral infiltrates (especially when CD4 < 200 and TB presents atypically)	TB often shows upper lobe predominance, cavitation (when CD4 is higher), or hilar/mediastinal lymphadenopathy. TB produces a productive cough, sometimes with hemoptysis. Sputum AFB smear/culture and positive nucleic acid amplification test distinguish TB.
CMV pneumonitis	Immunosuppressed host (especially transplant recipients) with bilateral interstitial infiltrates and hypoxia	CMV pneumonitis is more common in transplant recipients than in HIV. Look for concurrent CMV retinitis or viremia. BAL with cytology showing owl-eye intranuclear inclusions confirms CMV.
Pulmonary Kaposi sarcoma	HIV/AIDS patient with dyspnea and bilateral pulmonary infiltrates	Kaposi sarcoma produces nodular lesions (not ground-glass) on imaging, often with associated pleural effusions and skin/mucosal violaceous lesions. Bronchoscopy reveals characteristic violaceous endobronchial plaques.
Mycobacterium avium complex (MAC)	AIDS patient with constitutional symptoms, fever, and weight loss	MAC typically occurs at CD4 < 50 (lower threshold than PCP). MAC is primarily a disseminated systemic disease (fever, hepatosplenomegaly, elevated alkaline phosphatase, cytopenias) rather than isolated pulmonary disease. Blood cultures are diagnostic.
Lymphocytic interstitial pneumonitis (LIP)	HIV-associated bilateral interstitial infiltrates with dyspnea	LIP predominantly affects children with HIV, not adults. It presents with reticulonodular infiltrates, parotid enlargement, and digital clubbing, developing over months.
Drug-induced pneumonitis (e.g., methotrexate lung)	Immunosuppressed patient on methotrexate with bilateral ground-glass opacities and dyspnea	History of methotrexate or bleomycin use, absence of elevated beta-D-glucan, and negative GMS/DFA staining on BAL. Temporal relationship to drug initiation is the key.

06Traps and High-Yield Pearls

The single most common way students lose points on PCP questions is by failing to add adjunctive corticosteroids when indicated. A vignette will describe an AIDS patient with bilateral ground-glass opacities and then provide an ABG showing $P a O_{2}$ of 55 mmHg. The student who selects "TMP-SMX alone" without corticosteroids will get the question wrong. Always check the oxygenation parameters: if $PaO_2 \leq 70$ or $A\text{-}a\ \text{gradient} \geq 35$ , steroids are mandatory and must be started before or with antibiotic therapy, not added later.

A second common trap is confusing the prophylaxis threshold with the treatment indication. Prophylaxis is initiated at CD4 < 200 regardless of symptoms. The vignette may present an asymptomatic HIV patient with a newly drawn CD4 of 180 and ask for the next best step, which is starting TMP-SMX prophylaxis, not observation or imaging.

A third pitfall involves the subacute timeline. If the vignette describes an immunocompromised patient with a cough that developed over "several weeks," this temporal pattern should immediately raise PCP in your differential. If the timeline is "2 days of high fever and productive cough," think bacterial pneumonia instead, even in an HIV-positive patient.

Students also forget that conventional antifungals do not work against P. jirovecii. Despite being classified as a fungus, its cell membrane lacks ergosterol. Amphotericin B, fluconazole, and voriconazole are all ineffective. If a question lists these as answer choices alongside TMP-SMX, they are distractors.

Finally, remember that TMP-SMX prophylaxis provides dual coverage against both PCP and toxoplasmosis. If the question asks about an HIV patient with CD4 < 100 who needs prophylaxis against both organisms, TMP-SMX one double-strength tablet daily covers both. Aerosolized pentamidine protects only against PCP (and only pulmonary, not extrapulmonary disease) and does not cover toxoplasmosis.

The core competency being tested across PCP questions is the ability to recognize the classic presentation in an immunosuppressed host (subacute dyspnea, dry cough, bilateral ground-glass opacities, elevated LDH), apply the correct severity assessment using ABG parameters, initiate appropriate treatment with steroids when indicated, and understand prophylaxis thresholds and discontinuation criteria.

LevelUp. Archive